{"0":{"dur":7,"text":"Translator: Gianna Carroni\nReviewer: Denise RQ"},"8":{"dur":5,"text":"Zika virus, dengue fever, chikungunya -"},"15":{"dur":4,"text":"these diseases, which are\nall spread by the Aedes mosquito,"},"20":{"dur":3,"text":"afflict millions of people\naround the world."},"24":{"dur":3,"text":"Very recently,\nthe World Health Organization"},"28":{"dur":2,"text":"for only the fourth time in its history,"},"31":{"dur":5,"text":"declared the current Zika outbreak\nas a global public health emergency."},"37":{"dur":4,"text":"Although these diseases\nhave been known for decades,"},"43":{"dur":4,"text":"no drug has ever been developed\nto treat any of them."},"48":{"dur":1,"text":"Why?"},"50":{"dur":3,"text":"Putting it simply,\ntheir markets are too small."},"54":{"dur":2,"text":"The cold heart truth"},"56":{"dur":6,"text":"is that it can cost billions of dollars\nand take decades to develop a new drug."},"62":{"dur":4,"text":"So, pharmaceutical companies,\nalmost invariably,"},"67":{"dur":5,"text":"only pursue drugs for diseases\nthat will generate large profits."},"73":{"dur":6,"text":"Unfortunately, this system is ill-suited\nfor diseases that primarily afflict"},"80":{"dur":4,"text":"the poor of the world,\nthe so-called neglected diseases."},"86":{"dur":5,"text":"The Centers for Disease Control in Atlanta\nestimate that annually"},"92":{"dur":5,"text":"three billion people worldwide are at risk\nfor contracting a neglected disease;"},"98":{"dur":4,"text":"and of them, more than a half million\nwill die each year."},"104":{"dur":4,"text":"So just imagine\nthe humanitarian impact we could have"},"109":{"dur":2,"text":"if we could devise a viable system"},"112":{"dur":6,"text":"for discovering and bringing to market\nnew drugs for neglected diseases."},"119":{"dur":5,"text":"In 1990, when this picture\nof a young man dying of AIDS"},"124":{"dur":3,"text":"appeared on the cover of Life magazine,"},"128":{"dur":1,"text":"the virus was taking the lives"},"130":{"dur":4,"text":"of some of our most creative\nand promising individuals."},"135":{"dur":3,"text":"At that time, AIDS was a neglected disease"},"138":{"dur":3,"text":"because infected patients\ndidn't survive long enough"},"142":{"dur":3,"text":"to create a sustainable market."},"146":{"dur":1,"text":"During that period,"},"148":{"dur":3,"text":"I was an Organic Chemistry Professor\nat Emory University"},"151":{"dur":4,"text":"and saw an opportunity to use\nmy skills and experience"},"156":{"dur":4,"text":"to try to bring\nthis heartless killer under control."},"161":{"dur":2,"text":"So I made it my personal goal"},"164":{"dur":3,"text":"to create drugs that were so effective"},"167":{"dur":2,"text":"that AIDS could be transformed"},"170":{"dur":4,"text":"from a death sentence\nto a manageable disease."},"177":{"dur":5,"text":"After some time, my lab was able\nto prepare some promising new compounds"},"183":{"dur":6,"text":"and file our first US patent application\non them on February 1, 1990,"},"189":{"dur":5,"text":"which, fortuitously,\nwas seven days ahead of our competition."},"197":{"dur":2,"text":"This proved to be the critical step"},"199":{"dur":5,"text":"in securing our rights to the drugs\nLamivudine and Emtricitabine,"},"205":{"dur":3,"text":"both of which have\ndramatically transformed"},"208":{"dur":3,"text":"how we treat HIV-infected patients."},"213":{"dur":1,"text":"By the time"},"214":{"dur":4,"text":"the first combination therapies\nfor AIDS came along in the mid 90s,"},"219":{"dur":6,"text":"patients were required to take\n15 to 20 pills each day."},"225":{"dur":3,"text":"Some before they ate, some after they ate."},"230":{"dur":2,"text":"Due to the complexity of these regimens,"},"232":{"dur":4,"text":"non-complying patients were at risk\nfor developing resistance."},"239":{"dur":2,"text":"By 2006, however,"},"241":{"dur":2,"text":"patients could take Atripla,"},"244":{"dur":4,"text":"which combines three drugs,\none of which is Emtricitabine,"},"249":{"dur":2,"text":"into a single daily dose."},"253":{"dur":4,"text":"This regimen has proven\nto be so effective"},"257":{"dur":5,"text":"that patients on it can live\nnearly normal lives for decades."},"264":{"dur":2,"text":"In the US, we estimate"},"266":{"dur":5,"text":"that over 90%\nof all HIV-infected patients on therapy"},"273":{"dur":3,"text":"take or have taken our drug."},"277":{"dur":3,"text":"This success, which is heartwarming,"},"280":{"dur":4,"text":"also demonstrates\nthat drugs can come from sources"},"284":{"dur":2,"text":"other than pharmaceutical companies."},"287":{"dur":2,"text":"But there was a downside."},"290":{"dur":5,"text":"It took 13 years to develop Emtricitabine."},"295":{"dur":1,"text":"I've often wondered"},"297":{"dur":3,"text":"how many patients died during that time."},"301":{"dur":3,"text":"Clearly, we needed\na better way to develop drugs;"},"305":{"dur":3,"text":"especially drugs for neglected diseases."},"309":{"dur":3,"text":"To do this, we have to find new ways"},"312":{"dur":3,"text":"of catalyzing more research\nin these areas."},"316":{"dur":5,"text":"One very innovative way\nis through networking organizations,"},"321":{"dur":2,"text":"like WIPO Re: Search,"},"323":{"dur":5,"text":"that match innovators\nwith potential partners,"},"329":{"dur":6,"text":"and create a speed dating mechanism\nfor early-stage therapeutics development."},"336":{"dur":1,"text":"Secondly,"},"338":{"dur":4,"text":"we need to overcome a major funding gap\nin the development process"},"343":{"dur":2,"text":"known as 'the valley of death, '"},"346":{"dur":4,"text":"where promising technologies\ncan wither and die,"},"350":{"dur":4,"text":"due to insufficient infrastructures\nand resources."},"356":{"dur":1,"text":"At present,"},"357":{"dur":6,"text":"most neglected disease research\nis funded by philanthropy."},"364":{"dur":3,"text":"But with just philanthropic funding,"},"367":{"dur":3,"text":"it's hard to sustain\na development process"},"371":{"dur":3,"text":"that can take a decade\nor more to complete."},"375":{"dur":2,"text":"As one possible solution to this,"},"377":{"dur":4,"text":"we invested some\nof our Emtricitabine patent royalties"},"382":{"dur":5,"text":"into a small non-profit drug development\ncompany called DRIVE,"},"387":{"dur":3,"text":"an acronym for Drug Innovation Ventures."},"391":{"dur":3,"text":"DRIVE is led by a team\nof highly experienced scientists,"},"394":{"dur":3,"text":"many of whom have previously\ndeveloped antiviral drugs."},"400":{"dur":3,"text":"Without shareholders or investors,"},"403":{"dur":4,"text":"DRIVE can focus\non the most critical unmet needs"},"409":{"dur":3,"text":"rather than those that might\ngenerate the largest profits."},"414":{"dur":5,"text":"DRIVE's focus is on\nsingle-stranded viral RNA infections."},"421":{"dur":7,"text":"These infections, which have by and large\nonly modest commercial potential,"},"429":{"dur":4,"text":"account for approximately 80%"},"433":{"dur":1,"text":"- eight-zero -"},"434":{"dur":3,"text":"of our worldwide viral disease burden."},"439":{"dur":3,"text":"By pursuing a mixed portfolio"},"443":{"dur":3,"text":"of major market and neglected diseases,"},"446":{"dur":2,"text":"DRIVE was able to use revenues"},"448":{"dur":4,"text":"obtained from the sale\nof a major market antiviral patent"},"452":{"dur":4,"text":"to subsidize research\non neglected viral disease."},"457":{"dur":1,"text":"Thanks to lessons learned,"},"460":{"dur":2,"text":"this process only took 15 months,"},"463":{"dur":1,"text":"which is notable,"},"464":{"dur":5,"text":"since the comparable process\nfor Emtricitabine took four years."},"472":{"dur":5,"text":"How can we translate\nDRIVE's proof of concept"},"479":{"dur":2,"text":"into a worldwide framework"},"482":{"dur":5,"text":"that will allow us to more rapidly address\nneglected diseases?"},"489":{"dur":4,"text":"How can we, as a global community,"},"493":{"dur":3,"text":"assemble the pieces necessary"},"496":{"dur":5,"text":"to discover new drugs,\nto treat the diseases of the poor,"},"502":{"dur":5,"text":"like Zika virus, like dengue fever,\nlike chikungunya?"},"509":{"dur":2,"text":"Over the past 15 years,"},"511":{"dur":3,"text":"I've worked extensively in Africa,"},"515":{"dur":4,"text":"with drug development scientists\nand entrepreneurs."},"519":{"dur":4,"text":"I've seen firsthand\nthe quality of their science"},"524":{"dur":5,"text":"and the passion they bring to diseases\nthat affect their own local communities."},"531":{"dur":6,"text":"So, selecting Africa as the first\ntarget region for a worldwide initiative"},"538":{"dur":1,"text":"seemed obvious."},"540":{"dur":5,"text":"In November 2015, we entered\ninto a formal partnership with ANDI,"},"546":{"dur":5,"text":"the African Network for Drugs\nand Diagnostics Innovation,"},"551":{"dur":3,"text":"which is a UN-based organization\nheadquartered in Addis Abeba."},"556":{"dur":3,"text":"Our partnership with ANDI\nhas two components,"},"559":{"dur":4,"text":"the first of which involves\nteaching African scientists"},"564":{"dur":5,"text":"about the business and legal aspects\nof the bio-pharmaceutical sector,"},"570":{"dur":3,"text":"helped in part by our colleagues\nhere in Geneva,"},"574":{"dur":3,"text":"at the World Intellectual\nProperty Organization."},"577":{"dur":6,"text":"The participants will be selected from\nthe over 40 ANDI Centres of Excellence"},"585":{"dur":3,"text":"and will be taught the intricacies"},"588":{"dur":3,"text":"of creating\npharmaceutical development plans,"},"591":{"dur":3,"text":"as well as the intellectual property\nmanagements skills"},"595":{"dur":3,"text":"needed to support those plans."},"600":{"dur":5,"text":"The second component of our partnership\ninvolves the creation of regional hubs"},"605":{"dur":2,"text":"distributed around Africa"},"608":{"dur":3,"text":"that are modeled after DRIVE"},"611":{"dur":3,"text":"and leverage ANDI's expertise"},"615":{"dur":3,"text":"at promoting\nAfrican-led health innovations."},"619":{"dur":5,"text":"Just like with DRIVE, each hub\nwill devote part of its attention"},"625":{"dur":2,"text":"to a major market disease"},"627":{"dur":3,"text":"and use revenues\nobtained from those activities"},"630":{"dur":3,"text":"to subsidize research\non neglected diseases."},"634":{"dur":1,"text":"Importantly,"},"637":{"dur":2,"text":"since this model involves partnerships"},"639":{"dur":3,"text":"between government\nand non-government agencies,"},"643":{"dur":3,"text":"we can assure that drugs\nderived from this initiative"},"648":{"dur":4,"text":"will be affordably priced\nand accessible to all."},"656":{"dur":6,"text":"Imagine a world\nwhere important healthcare innovations"},"663":{"dur":5,"text":"emerge from networks\nof focused scientists and entrepreneurs"},"671":{"dur":4,"text":"operating through creative\nnon-profit structures."},"678":{"dur":4,"text":"Imagine a world\nwhere today's neglected diseases"},"684":{"dur":2,"text":"become tomorrow's manageable conditions;"},"686":{"dur":2,"text":"just as we saw with AIDS."},"691":{"dur":4,"text":"Imagine a world where companies\nthat focus on neglected diseases"},"696":{"dur":4,"text":"do good and do well at the same time."},"701":{"dur":2,"text":"Even better: imagine a world"},"704":{"dur":4,"text":"where neglected diseases\nare things of the past."},"710":{"dur":1,"text":"Thank you."},"711":{"dur":1,"text":"(Applause)"}}